PAP
TGTX icon

Persistent Asset Partners’s TG Therapeutics TGTX Stock Holding History

Persistent Asset Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3K Buy
+193
New +$7.9K 0.01% 613
2025
Q1 		– Sell
-295
Closed -$5.12K – 211
2024
Q4 		$5.12K Buy
+295
New +$8.47K ﹤0.01% 134

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Persistent Asset Partners's TGTX Position: Q2 2026 in Review

Persistent Asset Partners sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 53,080 shares — an estimated $2.17M sold.

Persistent Asset Partners first reported a position in TGTX in Q4 2024 and held it in 6 quarters. The position peaked at $3.08M in Q2 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Persistent Asset Partners reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 53,080 TG Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Persistent Asset Partners first reported a position in TG Therapeutics in Q4 2024 and held it in 6 quarters.
  • Persistent Asset Partners's TG Therapeutics position peaked at $3.08M in Q2 2025.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.